市場調查報告書

化療誘發性噁心和嘔吐(CINV)的全球市場:2020年∼2024年

Global Chemotherapy-induced Nausea and Vomiting Drugs Market 2020-2024

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 951846
出版日期 內容資訊 英文 120 Pages
商品交期: 最快1-2個工作天內
價格
化療誘發性噁心和嘔吐(CINV)的全球市場:2020年∼2024年 Global Chemotherapy-induced Nausea and Vomiting Drugs Market 2020-2024
出版日期: 2020年07月06日內容資訊: 英文 120 Pages
簡介

化療誘發性噁心和嘔吐(CINV)市場在2020年∼2024年間,預測將成長到5億2,500萬美元,在預測期間內的年複合成長率將是5%。市場成長的主要因素有癌症人口的增加,新藥的認證更推動了市場成長。

本報告提供化療誘發性噁心和嘔吐(CINV)市場調查,提供市場概要,市場成長要素及阻礙因素分析,各類型·各地區的市場規模的變化與預測,供應商分析,市場機會等全面性資訊。

目錄

摘要整理

市場形勢

市場規模

  • 市場定義
  • 市場區隔分析
  • 2019年的市場規模
  • 市場預測:從2019年∼2024年的預測

波特的五力分析

各療法市場區隔

  • 市場·市場區隔
  • 各治療法比較
  • 血清素受體拮抗劑-市場規模與預測(2019年∼2024年)
  • NK1受體拮抗劑-市場規模與預測(2019年∼2024年)
  • 其他-市場規模與預測(2019年∼2024年)
  • 各治療法市場機會

客戶形勢

各地區形勢

  • 各地區市場區隔
  • 各地區比較
  • 北美 -市場規模與預測(2019年∼2024年)
  • 歐洲-市場規模與預測(2019年∼2024年)
  • 亞太地區-市場規模與預測(2019年∼2024年)
  • 其他地區-市場規模與預測(2019年∼2024年)
  • 主要國家
  • 地區的市場機會
  • 市場成長要素
  • 市場課題
  • 市場趨勢

業者情勢

  • 業者情勢
  • 創造性破壞狀況

供應商分析

  • 交易廠商
  • 供應商的市場定位
  • Baxter International Inc.
  • Cipla Inc.
  • Dr. Reddy's Laboratories Ltd.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Merck & Co. Inc.
  • Mylan NV
  • Novartis AG
  • Sanofi
  • Sun Pharmaceutical Industries Ltd.

附錄

目錄
Product Code: IRTNTR44291

Technavio has been monitoring the chemotherapy-induced nausea and vomiting drugs market and it is poised to grow by $ 525 mn during 2020-2024 progressing at a CAGR of 5% during the forecast period. Our reports on chemotherapy-induced nausea and vomiting drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the growing cancer population driving the market growth and approval of new drugs fuels the market growth.

Chemotherapy-induced nausea and vomiting drugs market analysis includes therapy segment and geographic landscapes

Technavio's ‘chemotherapy-induced nausea and vomiting drugs market ’ is segmented as below:

By Therapy:

  • Serotonin receptor antagonists
  • NK1 receptor antagonists
  • Others

By Geographic Landscape:

  • North America
  • Europe
  • APAC
  • ROW

This study identifies the growing preference for chemotherapy drugs in developing countries as one of the prime reasons driving chemotherapy-induced nausea and vomiting drugs market growth during the next few years.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our chemotherapy-induced nausea and vomiting drugs market covers the following areas:

  • Chemotherapy-induced nausea and vomiting drugs market sizing
  • Chemotherapy-induced nausea and vomiting drugs market forecast
  • Chemotherapy-induced nausea and vomiting drugs market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading chemotherapy-induced nausea and vomiting drugs market vendors that include Baxter International Inc., Cipla Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Merck & Co. Inc., Mylan NV, Novartis AG, Sanofi, and Sun Pharmaceutical Industries Ltd. Also, chemotherapy-induced nausea and vomiting drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Table of Contents

Executive Summary

  • Market Overview

Market Landscape

  • Market ecosystem
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2019
  • Market outlook: Forecast for 2019 - 2024

Five Forces Analysis

  • Five forces summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Therapy

  • Market segments
  • Comparison by Therapy
  • Serotonin receptor antagonists - Market size and forecast 2019-2024
  • NK1 receptor antagonists - Market size and forecast 2019-2024
  • Others - Market size and forecast 2019-2024
  • Market opportunity by Therapy

Customer landscape

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • APAC - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity by geography
  • Market drivers
  • Market challenges
  • Market trends

Vendor Landscape

  • Vendor landscape
  • Landscape disruption

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • Baxter International Inc.
  • Cipla Inc.
  • Dr. Reddy's Laboratories Ltd.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Merck & Co. Inc.
  • Mylan NV
  • Novartis AG
  • Sanofi
  • Sun Pharmaceutical Industries Ltd.

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

Exhibit

  • 1: Key Finding 1
  • 2: Key Finding 2
  • 3: Key Finding 3
  • 4: Key Finding 5
  • 5: Key Finding 6
  • 6: Key Finding 7
  • 7: Key Finding 8
  • 8: Parent market
  • 9: Market characteristics
  • 10: Offerings of vendors included in the market definition
  • 11: Market segments
  • 12: Global - Market size and forecast 2019 - 2024 ($ million)
  • 13: Global market: Year-over-year growth 2019 - 2024 (%)
  • 14: Five forces analysis 2019 & 2024
  • 15: Bargaining power of buyers
  • 16: Bargaining power of suppliers
  • 17: Threat of new entrants
  • 18: Threat of substitutes
  • 19: Threat of rivalry
  • 20: Market condition - Five forces 2019
  • 21: Other1 - Market share 2019-2024 (%)
  • 22: Comparison by Other1
  • 23: Serotonin receptor antagonists - Market size and forecast 2019-2024 ($ million)
  • 24: Serotonin receptor antagonists - Year-over-year growth 2019-2024 (%)
  • 25: NK1 receptor antoagonists - Market size and forecast 2019-2024 ($ million)
  • 26: NK1 receptor antoagonists - Year-over-year growth 2019-2024 (%)
  • 27: Others - Market size and forecast 2019-2024 ($ million)
  • 28: Others - Year-over-year growth 2019-2024 (%)
  • 29: Market opportunity by Other1
  • 30: Customer landscape
  • 31: Market share by geography 2019-2024 (%)
  • 32: Geographic comparison
  • 33: North America - Market size and forecast 2019-2024 ($ million)
  • 34: North America - Year-over-year growth 2019-2024 (%)
  • 35: Europe - Market size and forecast 2019-2024 ($ million)
  • 36: Europe - Year-over-year growth 2019-2024 (%)
  • 37: APAC - Market size and forecast 2019-2024 ($ million)
  • 38: APAC - Year-over-year growth 2019-2024 (%)
  • 39: ROW - Market size and forecast 2019-2024 ($ million)
  • 40: ROW - Year-over-year growth 2019-2024 (%)
  • 41: Key leading countries
  • 42: Market opportunity by geography ($ million)
  • 43: Impact of drivers and challenges
  • 44: Vendor landscape
  • 45: Landscape disruption
  • 46: Industry risks
  • 47: Vendors covered
  • 48: Market positioning of vendors
  • 49: Baxter International Inc. - Overview
  • 50: Baxter International Inc. - Business segments
  • 51: Baxter International Inc. - Key offerings
  • 52: Baxter International Inc. - Key customers
  • 53: Baxter International Inc. - Segment focus
  • 54: Cipla Inc. - Overview
  • 55: Cipla Inc. - Business segments
  • 56: Cipla Inc. - Key offerings
  • 57: Cipla Inc. - Key customers
  • 58: Cipla Inc. - Segment focus
  • 59: F. Hoffmann-La Roche Ltd. - Overview
  • 60: F. Hoffmann-La Roche Ltd. - Business segments
  • 61: F. Hoffmann-La Roche Ltd. - Key offerings
  • 62: F. Hoffmann-La Roche Ltd. - Key customers
  • 63: F. Hoffmann-La Roche Ltd. - Segment focus
  • 64: GlaxoSmithKline Plc - Overview
  • 65: GlaxoSmithKline Plc - Business segments
  • 66: GlaxoSmithKline Plc - Key offerings
  • 67: GlaxoSmithKline Plc - Key customers
  • 68: GlaxoSmithKline Plc - Segment focus
  • 69: Merck & Co. Inc. - Overview
  • 70: Merck & Co. Inc. - Business segments
  • 71: Merck & Co. Inc. - Key offerings
  • 72: Merck & Co. Inc. - Key customers
  • 73: Merck & Co. Inc. - Segment focus
  • 74: Mylan NV - Overview
  • 75: Mylan NV - Business segments
  • 76: Mylan NV - Key offerings
  • 77: Mylan NV - Key customers
  • 78: Mylan NV - Segment focus
  • 79: Novartis AG - Overview
  • 80: Novartis AG - Business segments
  • 81: Novartis AG - Key offerings
  • 82: Novartis AG - Key customers
  • 83: Novartis AG - Segment focus
  • 84: Sanofi - Overview
  • 85: Sanofi - Business segments
  • 86: Sanofi - Key offerings
  • 87: Sanofi - Key customers
  • 88: Sanofi - Segment focus
  • 89: Sun Pharmaceutical Industries Ltd. - Overview
  • 90: Sun Pharmaceutical Industries Ltd. - Business segments
  • 91: Sun Pharmaceutical Industries Ltd. - Key offerings
  • 92: Sun Pharmaceutical Industries Ltd. - Key customers
  • 93: Sun Pharmaceutical Industries Ltd. - Segment focus
  • 94: Currency conversion rates for US$
  • 95: Research Methodology
  • 96: Validation techniques employed for market sizing
  • 97: Information sources
  • 98: List of abbreviations